Sugi Predict

Sugi Predict / Compounds / SCHEMBL1243890

SCHEMBL1243890

SCHEMBL1243890

NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(=O)O)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 1/20 0.57
▸ GNPAT O15228 2/20 0.55
▸ GSR P00390 1/20 0.46
▸ CPB2 Q96IY4 5/20 0.44
▸ SLC15A2 Q16348 1/20 0.43
▸ ERAP2 Q6P179 1/20 0.42
▸ ERAP1 Q9NZ08 1/20 0.42
▸ LNPEP Q9UIQ6 1/20 0.42
▸ SLC6A5 Q9Y345 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29759596 1.00 FOLH1 (0.57) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL30584460 1.00 FOLH1 (0.57) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL1243885 1.00 FOLH1 (0.57) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL30099636 0.99 FOLH1 (0.56) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL29642057 0.95 GNPAT (0.56) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL29642037 0.95 GNPAT (0.56) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL29642036 0.95 GNPAT (0.56) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL29642073 0.95 GNPAT (0.56) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL29642040 0.95 GNPAT (0.56) FOLH1GNPATGSRCPB2SLC15A2
SCHEMBL29860303 0.95 FOLH1 (0.55) FOLH1GNPATGSRCPB2SLC15A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192431-A Self-assembled polypeptide probe for enhancing tumor magnetic resonance imaging 东南大学 2025-06-24 — — CN claimed
US-20240384007-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2024-11-21 — — US claimed
US-11999802-B2 Compositions and methods for selective protein degradation NOVARTIS AG (CH) 2024-06-04 — — US claimed
EP-4219721-A2 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION Novartis AG (CH) 2023-08-02 — — EP claimed
US-20230174933-A1 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS NOVARTIS AG (CH) 2023-06-08 — — US claimed
US-20230071283-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION Payne, Aimee S. (US) 2023-03-09 — — US claimed
EP-3443096-B1 COMPOSITIONS AND METHODS FOR SELECTIVE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS NOVARTIS AG (CH) 2023-03-01 — — EP claimed
EP-4110377-A2 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS Novartis AG (CH) 2023-01-04 — — EP claimed
US-20220307053-A1 REGULATABLE EXPRESSION SYSTEMS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-09-29 — — US claimed
EP-4004213-A1 REGULATABLE EXPRESSION SYSTEMS Novartis AG (CH) 2022-06-01 — — EP claimed
CN-114174514-A Adjustable expression system 诺华股份有限公司 2022-03-11 — — CN claimed
US-5627268-A MAKING A DESIRED PEPTIDE IN TRANSGENIC ANIMALS DNX BIOTHERAPEUTICS (US) 1997-05-06 — — US claimed
US-5356781-A Zymogen activation peptides (ZAP) in the diagnosis of disease BIOSCIENCE INTERNATIONAL, INC. (US) 1994-10-18 — — US claimed
CN-122084779-A Reversed phase chromatographic analysis method for enterokinase protein purity — 2026-05-26 — — CN disclosed
US-20260130938-A1 NOVEL RECEPTORS FOR TRANSCRIPTION REGULATION ARSENAL BIOSCIENCES INC (US) 2026-05-14 — — US disclosed
EP-4727962-A2 SINGLE-AND MULTI-CYTOKINE FUSION PROTEINS AND USES THEREOF Fuse Biotherapeutics Inc. (US) 2026-04-22 — — EP disclosed
WO-1992001707-A1 PURIFICATION DIRECTED CLONING OF PEPTIDES BIONEBRASKA, INC. (US) 1992-02-06 — — WO disclosed
US-4948723-A ASSAYING BODY FLUIDS FOR ACTIVATION PEPTIDES OF PANCREATIV ZYMOGENS CLEAVED BY PROTEOLYSIS BIOSCIENCE INTERNATIONAL, INC. (US) 1990-08-14 — — US disclosed
EP-0258995-A1 Diagnosis, severity prediction, and monitoring of disease by immunoassay of free activation peptides of pancreatic zymogens BIOSCIENCE INTERNATIONAL, INC. (US) 1988-03-09 — — EP disclosed
WO-1988001059-A1 DIAGNOSIS OF PANCREATIC DISEASE BIOSCIENCE INTERNATIONAL INC. (US) 1988-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230071283-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION BCL6, BCL3, BCL6B FOLH1 785/4885GNPAT 3868/4885GSR 4599/4885
US-20260130938-A1 NOVEL RECEPTORS FOR TRANSCRIPTION REGULATION TMIGD3, TMPRSS11D, TM9SF2 FOLH1 2929/4885GNPAT 4806/4885GSR 4676/4885
US-20240384007-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION CRBN, RPS27A, COPB1 FOLH1 2290/4885GNPAT 3812/4885GSR 4640/4885
US-11999802-B2 Compositions and methods for selective protein degradation CRBN, RPS27A, COPB1 FOLH1 2290/4885GNPAT 3812/4885GSR 4640/4885
US-20230174933-A1 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS HAVCR2, MICA, CD74 FOLH1 508/4885GNPAT 3474/4885GSR 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.